Violation Tracker Individual Record
Date:August 17, 2017
Primary Offense:False Claims Act
Mylan Inc. and Mylan Specialty L.P. agreed to pay $465 million to resolve claims that they violated the False Claims Act by knowingly misclassifying EpiPen as a generic drug to avoid paying rebates owed primarily to Medicaid.
Level of Government:federal
Action Type:agency action
Agency:Justice Department Civil Division
Civil or Criminal Case:civil
HQ Country of Parent:Netherlands (reincorporated for tax reasons)
Ownership Structure of Parent:publicly traded
Major Industry of Parent:pharmaceuticals
Specific Industry of Parent:pharmaceuticals
Source of Data:
Source Notes:If an online information source is not working, check the Violation Tracker Data Sources page for an updated link.